Abstract
Nef is a viral pathogenicity factor that has an important role in disease progression associated with HIV infection. Yet, no antiviral drugs capable of inhibiting of Nef are available or in clinical trials today. In this review the challenges and potential involved in pharmaceutical targeting of Nef are discussed in light of current understanding of the molecular mechanisms of Nef action, with a special emphasis on effector functions of Nef that are mediated via SH3 domain-directed interactions with host cell proteins.
Keywords: nef, hiv, aids, protein interactions, signal transduction, drug screening
Current Drug Targets - Immune, Endocrine & Metabolic Disorders
Title: Therapeutic Targeting of Interactions Between Nef and Host Cell Proteins
Volume: 4 Issue: 4
Author(s): Kalle Saksela
Affiliation:
Keywords: nef, hiv, aids, protein interactions, signal transduction, drug screening
Abstract: Nef is a viral pathogenicity factor that has an important role in disease progression associated with HIV infection. Yet, no antiviral drugs capable of inhibiting of Nef are available or in clinical trials today. In this review the challenges and potential involved in pharmaceutical targeting of Nef are discussed in light of current understanding of the molecular mechanisms of Nef action, with a special emphasis on effector functions of Nef that are mediated via SH3 domain-directed interactions with host cell proteins.
Export Options
About this article
Cite this article as:
Saksela Kalle, Therapeutic Targeting of Interactions Between Nef and Host Cell Proteins, Current Drug Targets - Immune, Endocrine & Metabolic Disorders 2004; 4 (4) . https://dx.doi.org/10.2174/1568005310404040315
DOI https://dx.doi.org/10.2174/1568005310404040315 |
Print ISSN 1568-0088 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5917 |
Related Articles
-
The Role of Growth Hormone, Insulin-Like Growth Factor and Somatostatin in Diabetic Retinopathy
Current Medicinal Chemistry Rikkunshito and Ghrelin Secretion
Current Pharmaceutical Design 18F-Fluoroestradiol Positron Emission Tomography in Breast Cancer Patients: Systematic Review of the Literature & Meta-Analysis
Current Radiopharmaceuticals Rat Resources in Biomedical Research
Current Pharmaceutical Biotechnology QSAR and Molecular Docking Studies on a Series of 1-Amino-5H-pyrido [4, 3-b]indol-4-carboxamides Acting as Janus Kinase 2 (JAK2) Inhibitors
Letters in Drug Design & Discovery Pancreatic β-Cells and Type 2 Diabetes Development
Current Diabetes Reviews Interventions Against Sarcopenia in Older Persons
Current Pharmaceutical Design Recent Advances in Therapeutic Peptides for Breast Cancer Treatment
Current Protein & Peptide Science Managing Expectations in the Transition to Proof of Concept Studies
Reviews on Recent Clinical Trials Interleukin-24: A Molecule with Potential Anti-Cancer Activity and a Cytokine in Search of a Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacogenomics of Human ABC Transporter ABCC11 (MRP8): Potential Risk of Breast Cancer and Chemotherapy Failure
Anti-Cancer Agents in Medicinal Chemistry Pomegranate Extracts and Cancer Prevention: Molecular and Cellular Activities
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Positron Emission Tomography (PET) Imaging of Biomolecules: From Chemical Labeling to Cancer Diagnostics
Mini-Reviews in Organic Chemistry Sensors Based On Carbon Nanotubes and Their Applications: A Review
Current Nanoscience Cancer as the Main Aging Factor for Humans: The Fundamental Role of 5-Methoxy-Tryptamine in Reversal of Cancer-Induced Aging Processes in Metabolic and Immune Reactions by Non-melatonin Pineal Hormones
Current Aging Science The Immunomodulatory Potential of Selected Bioactive Plant-Based Compounds in Breast Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry AMI and Anabolic-Androgenic Steroids: Case Report with Systematic Review
Current Cardiology Reviews Side Effects of AAS Abuse: An Overview
Mini-Reviews in Medicinal Chemistry γ δ T Cell Modulation in Anticancer Treatment
Current Cancer Drug Targets Biotransformation of Endocrine Disrupting Compounds by Selected Phase I and Phase II Enzymes – Formation of Estrogenic and Chemically Reactive Metabolites by Cytochromes P450 and Sulfotransferases
Current Medicinal Chemistry